Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer

Volumn 15, Issue 4, 2017, Pages e591-e597

  Miyake, Hideaki ^a,b   Hara, Takuto ^a   Tamura, Keita ^b   Sugiyama, Takayuki ^b   Furuse, Hiroshi ^b   Ozono, Seiichiro ^b   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Abiraterone acetate; Cross resistance; Enzalutamide; Sequential therapy

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PHENYLTHIOHYDANTOIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ABIRATERONE ACETATE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85008474030     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.12.015     Document Type: Article

References (18)

1. Graham, L., Schweizer, M.T., Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Med Oncol, 33, 2016, 44.
2. Fizazi, K., Scher, H.I., Molina, A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992.
3. Ryan, C.J., Smith, M.R., Fizazi, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
4. Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
5. Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
6. Chi, K., Hotte, S.J., Joshua, A.M., et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 26 (2015), 2044–2056.
7. Noonan, K.L., North, S., Bitting, R.L., et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24 (2013), 1802–1807.
8. Brasso, K., Thomsen, F.B., Schrader, A.J., et al. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur Urol 68 (2015), 317–324.
9. Badrising, S., van der Noort, V., van Oort, I.M., et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 120 (2014), 968–975.
10. Bianchini, D., Lorente, D., Rodriguez-Vida, A., et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 50 (2014), 78–84.
11. Schrader, A.J., Boegemann, M., Ohlmann, C.H., et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65 (2014), 30–36.
12. Azad, A.A., Eigl, B.J., Murray, R.N., et al. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 67 (2015), 23–29.
13. Suzman, D.L., Luber, B., Schweizer, M.T., et al. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 74 (2014), 1278–1285.
14. Maughan, B.L., Luber, B., Nadal, R., et al. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate 77 (2017), 33–40.
15. Nadal, R., Tsai, H.L., Sinibaldi, V.J., et al. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. Prostate 76 (2016), 512–520.
16. Miyake, H., Hara, T., Ozono, S., et al. Impact of prior use of an androgen receptor-axis-targeted (ARAT) agent with or without subsequent taxane therapy on the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer [e-pub ahead of print]. Clin Genitourin Cancer, 2016 http://dx.doi.org/10.1016/j.clgc.2016.07.005.
17. Miyake, H., Hara, T., Terakawa, T., et al. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan [e-pub ahead of print]. Clin Genitourin Cancer, 2016 http://dx.doi.org/10.1016/j.clgc.2016.06.010.
18. Parimi, S., Chi, K.N., Chemotherapy for metastatic castration-sensitive prostate cancer. Int J Urol 23 (2016), 726–733.